Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Applications of Mass Spectrometry

Janne Lehtio's Biography

Janne Lehtio, Associate Professor, Karolinska Institutet

Associate Professor Janne Lehtiö has since 2004 lead Karolinska University Hospital’s clinical proteomics research facility and since 2010 he is platform director of clinical proteomics mass spectrometry facility at the national research center Science for Life Laboratory, Sweden. Since 2008, Lehtiö has been principle investigator at Dept. of Oncology and Pathology leading the cancer proteomics research group at Karolinska Institutet (KI), Sweden.
Janne Lehtiö accomplished a Master of Science in Biochemistry in university of Helsinki, Finland. For his doctoral studies, he moved to Royal Institute of Technology, Stockholm, Sweden and completed his PhD in Biotechnology in 2001. Lehtiö completed a postdoc period in cancer research 2003 at Karolinska Institutet. In 2009, Lehtiö was granted an Associate Professorship in Proteomics at Karolinska Institutet, Sweden.
Dr Lehtiö’s major research interest is to improve human proteome analysis and to use this in-depth proteome information to personalize cancer therapy. Lehtiö’s group has published number of methods to improve proteome analysis in leading journals and applied these methods in biomarker and disease mechanism studies. He has developed high resolution peptide isoelectric focusing for in-depth analysis of clinical samples and for proteogenomics.
Janne Lehtiö has supervised 9 PhD students and 14 postdoctoral fellows. Currently, Lehtiö is leading the cancer proteomics research group of 20 researchers and graduate students.

Janne Lehtio Image

Breast Cancer Biomarkers From Discovery to Early Validation by Proteomics

Wednesday, 29 October 2014 at 14:15

Add to Calendar ▼2014-10-29 14:15:002014-10-29 15:15:00Europe/LondonBreast Cancer Biomarkers From Discovery to Early Validation by ProteomicsClinical Applications of Mass Spectrometry in Barcelona, SpainBarcelona,

Proteome analysis revealed retinoic acid receptor as potential prognostic and predictive marker in endocrine resistant breast cancer. Further, in-depth quantitative proteome and proteogenomics analysis of breast cancer sub-types will be presented.

Add to Calendar ▼2014-10-29 00:00:002014-10-30 00:00:00Europe/LondonClinical Applications of Mass SpectrometryClinical Applications of Mass Spectrometry in Barcelona, SpainBarcelona,